Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer

PURPOSE: To determine the systemic exposure to cisplatin and paclitaxel after adjuvant intraperitoneal administration in patients with advanced ovarian cancer who underwent primary debulking surgery. This could provide an explanation for the high incidence of systemic adverse events associated with...

Descripción completa

Detalles Bibliográficos
Autores principales: de Jong, Loek A. W., Lambert, Marie, van Erp, Nielka P., de Vries, Lukas, Chatelut, Etienne, Ottevanger, Petronella B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10033566/
https://www.ncbi.nlm.nih.gov/pubmed/36892677
http://dx.doi.org/10.1007/s00280-023-04512-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10033566/
https://www.ncbi.nlm.nih.gov/pubmed/36892677
http://dx.doi.org/10.1007/s00280-023-04512-z

Ejemplares similares